Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis (ESTEEM 1)
2022년 3월 3일 업데이트: Amgen
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
This study evaluated the effects of an called apremilast.
Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.
The purpose of this study was to test apremilast and compare its effects to placebo (an inactive substance which contains no medicine but is in the same form as the drug).
This study was able to test for efficacy (improvement of signs and symptoms) and safety of apremilast in patients with moderate to severe psoriasis.
연구 개요
연구 유형
중재적
등록 (실제)
844
단계
- 3단계
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Males or females, ≥ 18 years of age at the time of signing the informed consent document
Diagnosis of chronic plaque psoriasis for at least 12 months prior to Screening
a. Have moderate to severe plaque psoriasis at Screening and Baseline
- Must meet all laboratory criteria
- Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of contraception as described by the Study Doctor while on study medication and for at least 28 days after taking the last dose of study medication
- Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane]) while on study medication and for a least 28 days after the last dose of study medication.
Exclusion Criteria:
Other than psoriasis, history of any clinically significant (as determined by the Investigator) or other major uncontrolled disease.
.
- Pregnant or breast feeding
- History of allergy to any component of the study drug
- Hepatitis B surface antigen positive at Screening
- Anti-hepatitis C antibody positive at Screening
- Active tuberculosis (TB) or a history of incompletely treated TB
- Clinically significant abnormality on 12-Lead Electrocardiogram (ECG) at Screening
- Clinically significant abnormal chest x-ray
- History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency
- Active substance abuse or a history of substance abuse within 6 months prior to Screening
- Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening
- Malignancy or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years)
- Psoriasis flare or rebound within 4 weeks prior to Screening
- Evidence of skin conditions that would interfere with clinical assessments
- Topical therapy within 2 weeks of randomization
- Systemic therapy for psoriasis within 4 weeks prior to randomization
- Use of phototherapy within 4 weeks prior to randomization (ie, Ultraviolet B (UVB), psoralen and ultraviolet A (PUVA)
- Adalimumab, etanercept, infliximab, or certolizumab pegol within 12 weeks prior to randomization
- Alefacept, briakinumab, or ustekinumab within 24 weeks prior to randomization
- Use of any investigational drug within 4 weeks prior to randomization
- Prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources
- Prior treatment with apremilast
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Apremilast
Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost).
At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
|
다른 이름들:
Identical matching placebo
|
|
위약 비교기: Placebo
Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
|
다른 이름들:
Identical matching placebo
|
|
활성 비교기: Apremilast 30 mg
Apremilast 30 mg by mouth (PO) twice a day (BID).
Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost).
At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study.
Non-responders or partial responders (PASI response <75) received additional topical therapies or phototherapy beginning at Week 32.
|
다른 이름들:
Identical matching placebo
At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) at Week 16 From Baseline
기간: Baseline to Week 16
|
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16.
The improvement in PASI score was used as a measure of efficacy.
The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions.
PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs.
Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).
The PASI score was set to missing if any severity score or degree of involvement is missing.
|
Baseline to Week 16
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
16주차에 가려움증 시각적 아날로그 척도(VAS) 점수의 기준선으로부터의 변화
기간: 기준선 및 16주차
|
Pruritus Visual Analog Scores(VAS)는 참가자가 경험하는 가려움증과 불편함의 양을 측정하는 데 사용되었습니다.
소양증(가려움증)에 대한 참가자 평가 질문: 평균적으로 지난 주에 귀하의 상태로 인해 가려움증이 어느 정도 있었습니까?
모든 VAS 값의 범위는 0~100입니다.
더 높은 점수는 더 심각한 증상 또는 질병에 해당합니다.
VAS 척도에 대해 기준선으로부터의 변화를 계산했습니다. 여기서 변화 = 방문 가치 - 기준선 가치입니다.
|
기준선 및 16주차
|
|
Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With At Least 2 Points Reduction From Baseline
기간: Baseline to Week 16
|
The sPGA was a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation.
When making the assessment of overall severity, the Investigator factored in areas that have already been cleared (ie, have scores of 0) and did not just evaluate remaining lesions for severity, ie, the severity of each sign was averaged across all areas of involvement, including cleared lesions.
In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score.
|
Baseline to Week 16
|
|
Percent Change From Baseline in Percent of Affected Body Surface Area (BSA) at Week 16
기간: Baseline and Week 16
|
BSA was a measurement of involved skin.
The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area.
BSA percent change from baseline (Visit 2 Week 0) was determined at each visit of the study, which is calculated as 100*(visit BSA - baseline BSA) / baseline BSA (%).
|
Baseline and Week 16
|
|
Percent Change From Baseline in the Psoriasis Area Severity Index (PASI) Score at Week 16
기간: Baseline to Week 16
|
Psoriasis Area Severity Index (PASI) scores range from 0 to 72, with higher scores reflecting greater disease severity.
Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs.
Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement).
The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant.
These values for each anatomic region are summed to yield the PASI score.
The PASI score was set to missing if any severity score or degree of involvement is missing.
PASI score percent change from baseline was calculated as 100* (visit score - baseline score)/baseline score (%).
|
Baseline to Week 16
|
|
Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score (PASI-50) at Week 16 From Baseline
기간: Baseline to Week 16
|
A participant was classified as having at least a 50% improvement in PASI score from baseline, which was equivalent to a percent change from baseline ranging from -100% to -50%.
PASI score is based on an assessment of erythema (reddening), induration (plaque thickness), desquamation (scaling), and the percent area affected as observed on the day of examination.
|
Baseline to Week 16
|
|
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16
기간: Baseline to Week 16
|
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease.
The instrument contains ten items dealing with the participant's skin.
With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0).
Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively).
The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
|
Baseline to Week 16
|
|
Change From Baseline in the Mental Component Summary (MSC) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16
기간: Baseline to Week 16
|
The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH).
Scale scores range from 0 to 100, with higher scores indicating better health.
Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS).
Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health.
For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.
|
Baseline to Week 16
|
|
Percentage of Participants Who Achieved Both a 75% Improvement (Response) in the PASI and sPGA Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction at Week 16 From Baseline
기간: Baseline to Week 16
|
PASI-75 response was the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16.
The improvement in PASI score was used as a measure of efficacy.
See Outcome Measure #1 for further description.
sPGA is a 5-point scale ranging from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation.
See OCM #2 for further description.
|
Baseline to Week 16
|
|
Kaplan Meier Estimate of Time to Loss of PASI-75 Response (Loss of Effect) at Week 32 During the Re-Randomized Treatment Withdrawal Phase
기간: Week 32 to Week 52
|
Time to loss was the time between the re-randomization date and the date of the first assessment where loss of PASI-75 was observed (event); or the time between the re-randomization date and the date of the last PASI assessment in the Weeks 32-52 interval prior to addition of protocol-prohibited medication/therapy, or resumption of APR 30 BID, or discontinuation, or Week 52 if no loss (censored).
|
Week 32 to Week 52
|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) During the Placebo-Controlled Phase
기간: Week 0 to Week 16; mean duration of exposure was 14.8 weeks and 15.0 weeks for subjects randomized to placebo and apremilast respectively.
|
An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study.
It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology.
Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE.
A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.
|
Week 0 to Week 16; mean duration of exposure was 14.8 weeks and 15.0 weeks for subjects randomized to placebo and apremilast respectively.
|
|
Number of Participants With TEAEs During the Apremilast-Exposure Period Through Week 260
기간: Week 0 to Week 260; mean exposure to apremilast 30 mg BID during the Apremilast-exposure Period up to Week 260 was 97.83 weeks
|
The Apremilast-exposure Period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast.
Adverse events that started after 28 days of initiating placebo and before resuming apremilast treatment in the Randomized Treatment Withdrawal Phase (Weeks 32 to 52) were excluded in the Apremilast-exposure Period.
A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above.
An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.
|
Week 0 to Week 260; mean exposure to apremilast 30 mg BID during the Apremilast-exposure Period up to Week 260 was 97.83 weeks
|
|
Number of Participants With a Psoriasis Flare or Rebound During the Placebo-Controlled Phase
기간: Weeks 0 to Week 16
|
Psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis.
Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued.
Note categories below.
[1] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase.
[2] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase.
[3] PASI >= 125% of baseline score at any visit after the last dose date for participants who discontinued within the phase and were not included in [1] and/or [2].
|
Weeks 0 to Week 16
|
|
Number of Participants With a Psoriasis Flare or Rebound During the During the Apremilast-exposure Period Through Week 260
기간: Week 0 to Week 260
|
Psoriasis flare was defined as a sudden intensification of psoriasis requiring medical intervention, or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis.
Rebound is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued.
Note categories below.
[1] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis) started on or after the first dose date and on or before the last dose date within the phase.
[2] Psoriasis adverse events (ie, preferred term as Guttate psoriasis, Psoriasis, Pustular psoriasis, Rebound psoriasis) started after the last dose date for participants who discontinued within the phase.
[3] PASI >= 125% of baseline score at any visit after the last dose date for participants who discontinued within the phase and were not included in [1] and/or [2].
|
Week 0 to Week 260
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2010년 9월 9일
기본 완료 (실제)
2012년 2월 23일
연구 완료 (실제)
2016년 11월 22일
연구 등록 날짜
최초 제출
2010년 8월 31일
QC 기준을 충족하는 최초 제출
2010년 9월 1일
처음 게시됨 (추정)
2010년 9월 2일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2022년 3월 15일
QC 기준을 충족하는 마지막 업데이트 제출
2022년 3월 3일
마지막으로 확인됨
2020년 4월 1일
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- CC-10004-PSOR-008
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .